Search clinical trials for: Multiple Dose Escalation

Total 31697 results

AEterna Zentaris
Dana-Farber Cancer Institute

Terminated

Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

Multiple Myeloma

Israel, Spain, Korea, Republic of, United States, Russian Federation, Canada, Ireland, Czechia, Slovakia
AbbVie (prior sponsor, Abbott)
Bristol-Myers Squibb

Completed

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

Hematologic Cancer
Dicerna Pharmaceuticals, Inc.

Terminated

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Multiple Myeloma | PNET | Solid Tumors | Non-Hodgkins Lymphoma | NHL | Pancreatic Neuroendocrine Tumors

United States
Bayer

Terminated

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

Psoriasis

Germany
National Cancer Institute (NCI)

Completed

Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

Multiple Myeloma

United States
GlaxoSmithKline

Terminated

NOGO-A in Multiple Sclerosis FTIH

Multiple Sclerosis

Australia
Barbara Ann Karmanos Cancer Institute
Eisai Inc.

Terminated

Dose Escalation Trial of Denileukin Diftitox (Ontak) Post Autologous Transplantation

Multiple Myeloma

United States
SCRI Development Innovations, LLC
Millennium Pharmaceuticals, Inc.; Cephalon

Completed

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

Multiple Myeloma

United States
Janssen-Cilag International NV

Completed

Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (OPTIMRETREAT)

Multiple Myeloma

France, Poland, Belgium, Germany, Israel, Portugal, Turkey, Finland, Sweden, Netherlands, Norway
Oncotherapeutics
Millennium Pharmaceuticals, Inc.

Terminated

Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

Multiple Myeloma

United States
Opexa Therapeutics, Inc.

Completed

Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis (DES)

Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis, Secondary Progressive

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients

Type 2 Diabetic Patients
Joseph Hazelton

Completed

A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)

Pain | Nausea | Vomiting

United States
Tibotec Pharmaceuticals, Ireland

Withdrawn

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

HIV Infections

Netherlands
Bayer

Withdrawn

Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

Multiple Myeloma

Belgium, Spain, Korea, Republic of, Taiwan, United States, Australia, Germany, Israel, Italy, Greece, Canada
IRCCS Centro di Riferimento Oncologico della Basilicata

Unknown

Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment. (REBOUND)

Multiple Myeloma
Threshold Pharmaceuticals

Unknown

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
Mayo Clinic

Completed

Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma

United States
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Phase 1, Randomized, Placebo-controlled, Single & Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Healthy Chinese Volunteers

Healthy
Sun Yat-sen University

Unknown

CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients

Rheumatoid Arthritis

China
University Hospital Freiburg
Merck Sharp & Dohme LLC; Janssen-Cilag Ltd.

Completed

Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) (VBDD)

Multiple Myeloma in Relapse

Germany
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

Solid Tumors

United States
Innate Pharma

Completed

An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb

Completed

Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma

United States
University of Pittsburgh
Novartis

Withdrawn

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse

United States
King's College Hospital NHS Trust

Completed

A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma (CRD)

Multiple Myeloma

United Kingdom
Bayer

Completed

Combined Single / Multiple Dose Escalation Study in Patients With Renal Anemia Due to CKD (Chronic Kidney Disease)

Anemia

Germany, United Kingdom
AstraZeneca
Nektar Therapeutics

Completed

A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

Opioid Induced Constipation (OIC)

United States
University Medical Center Groningen

Completed

Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance (REMM)

Multiple Myeloma

Netherlands
Icure Pharmaceutical Inc.

Completed

A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.

Alzheimer Disease

Korea, Republic of
Emory University
Millennium Pharmaceuticals, Inc.; Ortho Biotech, Inc.

Completed

Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

United States, Canada
Janssen-Cilag G.m.b.H

Completed

A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

Multiple Myeloma

Germany
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects

Pharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707

France
Janssen-Cilag International NV

Completed

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD (SEQUENTIAL)

Multiple Myeloma

France, United Kingdom, Spain, Poland, Serbia, Turkey, Greece, Germany, Hungary, Lithuania
National Cancer Institute (NCI)

Terminated

Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

Refractory Multiple Myeloma

United States
Janssen-Cilag G.m.b.H

Completed

A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

Multiple Myeloma

Germany
Sun Yat-sen University

Unknown

Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

Multiple Myeloma

China
PETHEMA Foundation

Completed

MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning (MINIALO-VELCAD)

Multiple Myeloma

Spain
Otsuka Pharmaceutical Development & Commercialization...

Completed

IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

Multiple Myeloma

United States, Canada
Boehringer Ingelheim

Completed

An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma
Pfizer

Completed

A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects

Healthy

Belgium
Pfizer

Completed

First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects

Healthy

United States
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma

Multiple Myeloma

France, Belgium, Germany, Spain, Portugal, Greece, Austria, Luxembourg
AVEO Pharmaceuticals, Inc.

Completed

A Phase 1 Dose-Escalation Study in Advanced Solid Tumors, Lymphomas or Multiple Myeloma (P05538)

Multiple Myeloma | Lymphomas | Malignant Solid Tumor

United States
H. Lee Moffitt Cancer Center and Research Institute
Millennium Pharmaceuticals, Inc.; Ortho Biotech, Inc.

Completed

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

Multiple Myeloma

United States
Sparrow Regional Cancer Center

Unknown

Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

Multiple Myeloma and Plasma Cell Neoplasm

United States
Biogen

Withdrawn

Dose Escalation Study to Evaluate the Penetration and Pharmacodynamic Effects of Baminercept in the Cerebrospinal Fluid (CSF)and Safety in Subjects With Secondary Progressive Multiple Sclerosis (SPMS)

Secondary Progressive Multiple Sclerosis
Millennium Pharmaceuticals, Inc.

Completed

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Waldenstrom Macroglobulinemia | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)

Multiple Myeloma

United States

3

Subscribe